Growth Expected in Veterinary Monoclonal Antibody Market!

Significant Growth in the Veterinary Monoclonal Antibody Market

The global veterinary monoclonal antibody market is expected to reach a value of 3.06 billion USD by 2030. This represents a significant increase from the anticipated value of 1.70 billion USD in 2025, with a projected compound annual growth rate (CAGR) of 12.4%. The growth is driven by increasing pet ownership and rising awareness of chronic diseases in pets.

Despite facing challenges such as rising pet care costs and stringent regulations, expanding treatment areas provide new opportunities. In particular, the canine segment holds the largest share of the market due to issues related to skin problems in dogs.

By 2030, the subcutaneous route of administration is expected to experience the fastest growth, supported by this easy method of application.

Market leaders include companies such as Zoetis, Elanco, and Merck & Co.. North America holds the largest share of the market due to its robust veterinary infrastructure and high pet ownership rates.

In 2024, the canine segment, which has the largest market share for dogs, is supported by increasing pet ownership and rising animal health expenditures. Dogs are frequently exposed to skin diseases such as allergies, fungal infections, and ectoparasitic infestations, necessitating frequent dermatological treatments.

Cytopoint became the largest segment in the market in 2024. Cytopoint is the first and only monoclonal antibody treatment approved by the FDA and EMA for the treatment of canine atopic dermatitis. Due to the increasing prevalence of atopic dermatitis, demand for Cytopoint is rising.

A thorough analysis reveals that the dermatology treatment area outperformed other segments in 2024. Growing awareness of dermatological treatment options is a key factor supporting market growth.

The future of the market is being shaped by the rise of veterinary hospitals and specialized centers that provide high-quality veterinary services. These centers will increase customer demand by offering comprehensive treatment options for various conditions.

North America holds the largest market share in 2024, due to its solid veterinary healthcare infrastructure and high rates of pet ownership. This region has a strong presence of market leaders making research and development investments in innovative monoclonal antibody therapies.